Galaxy Medicare Stock Price Today (NSE: GML)

Galaxy Medicare

16.70+0.00 (+0.00%)
Market Closed

Fundamental Score

...

Galaxy Medicare Share Price — Live NSE/BSE Price, Fundamentals & Analysis

Galaxy Medicare share price today is 16.70, up +0.00% on NSE/BSE as of 3 August 2026. Galaxy Medicare (GML) is a Small-cap company in the Medical Equipment & Supplies sector with a market capitalisation of 27.46 (Cr). The 52-week high for GML share price is 23.80 and the 52-week low is 16.20. At a P/E ratio of 8.03x, GML is currently trading below its industry average P/E of 36.70x. The company has a Return on Equity (ROE) of 10.61% and a debt-to-equity ratio of 0.10.

Galaxy Medicare Share Price Chart — NSE/BSE Historical Performance

No data
High
18.30
Low
16.25
Volume
4.5K
Change
-8.47%

Galaxy Medicare share price chart: -8.47% return over the past month. 52-week high ₹23.80, 52-week low ₹16.20.

Galaxy Medicare — Last 10 Trading Days

DateOpenHighLowCloseVolume
16.2516.7516.2516.754.00K (Cr)
16.8017.2016.8016.908.00K (Cr)
17.2017.2017.2017.204.00K (Cr)
17.6017.6017.6017.602.00K (Cr)
17.6017.6017.6017.602.00K (Cr)
17.5517.5517.5517.552.00K (Cr)
18.1518.1518.0018.1010.00K (Cr)
18.2518.3018.2518.304.00K (Cr)
19.5019.7519.5019.7512.00K (Cr)
18.1019.8018.1019.7510.00K (Cr)

Galaxy Medicare — Last 12 Months Price History

MonthOpenHighLowCloseChange
18.2518.3016.2516.75-8.22%
19.5019.7519.5019.75+1.28%
20.2520.2518.1019.75-2.47%
17.2519.6517.2519.20+11.30%
16.9018.0516.2017.30+2.37%
18.5019.5018.4018.40-0.54%
20.8522.4017.6017.90-14.15%
18.5523.8018.2022.00+18.60%
22.0022.9019.7519.75-10.23%

AI Research Briefing

Powered by Gemini · 2026-08-01

A illiquid micro-cap medical consumable supplier trapped in declining top-line growth and zero institutional interest.

Research Confidence
3.0/10Low
MICRO-CAP DARK HORSEconsolidation — 1M return at 1.12%, 3M at -9.5%, and 6M at -8.12% showing dead momentum.cheap — P/E of 8.03x vs industry P/E of 36.7x, but entirely justified by lack of scale and growth.

WHAT'S HAPPENING NOW (last 2-4 weeks)

Board of Galaxy Medicare recommended a final dividend of ₹0.35 per equity share following a financial year closure showing total revenue of ₹40.00 crores and net income of ₹3.42 crores for FY26. Trading activity remains heavily constrained by microcap liquidity limits, with daily volumes hovering around 4,000 shares and total traded values dipping under a lakh. No major fresh institutional order announcements or strategic expansions have hit the exchange wires over the last month.

CORE STORY (THE REAL GAME)

A micro-cap contract supplier of basic surgical dressings and plaster bandages trying to survive in a commoditized medical consumables segment while wrestling with absolute lack of institutional sponsorship and zero free float velocity.

Why Now
  • Latest FY26 revenue printed at ₹40.00 crores with net income softening to ₹3.42 crores.
  • Promoter holding steady at 72.98% with absolute zero FII and DII participation.
  • Volume drying up with daily traded values slipping below ₹1 lakh.
Potential Catalysts
  • Sudden bulk institutional entry into the SME segment
  • Massive government hospital supply contract wins exceeding ₹10 crores
  • Aggressive capacity expansion or product pivot toward high-margin medical devices
Key Risks
  • Severe micro-cap and SME liquidity risk with near-zero daily volume
  • Contraction in latest quarterly YoY sales by 3.14% and profit by 15.66%
  • Total absence of institutional sponsorship with DII exodus
Institutional Activity

Promoters hold 72.98% with a minor delta of 0.55%, while FII sits at 0.0% and DII completely exited with a 1.85% drop, leaving retail holding the bag.

Macro Context

India's broader medical device sector is expanding at an 8.30% CAGR toward USD 65.39 billion by 2034, but micro-caps like GML are completely detached from the structural tailwind.

Order Book / Expansion

No major institutional contract announcements or expansion orders found after live search.

Cash Flow Quality

yes — reported positive operating cash flow and free cash flow of ₹5.77 crores in FY25, though conversion has slowed down in FY26.

3–6 Month Outlook

Continued range-bound stagnation and downward drift due to total absence of buying volume. Expect further valuation compression.

Primary Thesis Risk

Complete lack of market liquidity combined with shrinking quarterly top-line revenues.

For educational purposes only. Not investment advice. Consult a SEBI-registered advisor before investing.

Returns & Performance

Poor

Return on Equity (ROE)

10.61%

Profit generated per ₹1 of shareholder equity

Poor

Return on Capital (ROCE)

13.62%

Returns generated on total capital deployed

Oper. Profit Margin (5Y Avg)

N/A

Average operating profit margin over 5 years

Good

Dividend Yield

1.93%

Annual dividend as % of current share price

Galaxy Medicare Valuation Check

Excellent

Price to Earnings (P/E)

8.03x

Share price ÷ earnings per share. Lower = cheaper

Poor

Industry Avg P/E

36.70x

Average P/E of all peers in this sector

Market-cap Classification
Small-cap
Higher growth potential with higher volatility.

Shareholding Pattern

Excellent

Promoter Holding

72.98%

% shares held by company founders/management

Poor

FII Holding

0.00%

% shares held by foreign institutional investors

Poor

DII Holding

0.00%

% held by domestic mutual funds, LIC, banks

Excellent

Promoter Pledged %

0.00%

% of promoter shares pledged as collateral — lower is safer

Growth Engine

Poor

Profit Growth (Quarterly YoY)

-15.66%

Net profit growth vs same quarter last year

Poor

Revenue Growth (Quarterly YoY)

-3.14%

Revenue growth vs same quarter last year

Poor

Revenue Growth (5-Year CAGR)

6.96%

Compounded annual revenue growth over 5 years

Poor

EPS Growth (5-Year CAGR)

-3.63%

Earnings per share growth over 5 years

Excellent

Net Profit Growth (5-Year CAGR)

35.10%

Compounded annual net profit growth over 5 years

Balance Sheet Health

Excellent

Debt to Equity Ratio

0.10x

Total debt ÷ equity. Below 0.5 = financially healthy

Excellent

Interest Coverage Ratio

17.82x

EBIT ÷ interest expense. Above 2.5 = can pay interest comfortably

Free Cash Flow (5-Year Total)

N/A

Cash left after capex over 5 years. Positive = self-funded growth

Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice

Galaxy Medicare Fundamental Analysis & Valuation Benchmarking

Educational evaluation of GML across key market metrics for learning purposes.

Positive Indicators

6 factors identified

Attractive Valuation (P/E: 8.03 vs Industry: 36.70)

Observation: Trading at discount to industry peers.

Analysis: P/E below industry average may present value opportunity.

Strong Profit Growth Track Record (35.10% CAGR)

Observation: Consistent 5-year profit compound annual growth rate.

Analysis: Profit CAGR >15% demonstrates scalable business model.

Conservative Debt Levels (D/E: 0.10)

Observation: Low leverage provides financial flexibility and reduced risk.

Analysis: Conservative debt structure offers resilience during economic downturns.

Strong Interest Coverage (17.82x)

Observation: Earnings comfortably cover interest obligations.

Analysis: Interest coverage >5x indicates low financial distress risk.

Balanced Promoter Holding (72.98%)

Observation: Optimal balance between promoter control and public float.

Analysis: Promoter holding in 50-75% range provides management alignment.

Zero Share Pledging Risk

Observation: No promoter shares pledged as collateral.

Analysis: Absence of share pledging eliminates potential forced-selling pressure.

Risk Factors

2 factors identified

Profit Decline Concern (-15.66%)

Observation: Significant year-over-year profit contraction observed.

Analysis: Declining profitability requires investigation into underlying causes.

Weak Earnings Growth (-3.63% CAGR)

Observation: Below-average 5-year EPS growth performance.

Analysis: Low EPS growth may not keep pace with inflation.

Galaxy Medicare vs Medical Equipment & Supplies Peers

Peer Comparison - Medical Equipment & Supplies

Compare Galaxy Medicare with 10 other companies in the same sector

11 companies
Company Info
Fundamental
Valuation
Profitability
Financial Health
Growth
Dividend
Company
Company name
Score
Bull Run comprehensive fundamental score based on 20+ metrics
Price
Current trading price of the stock
Market Cap
Total value of all shares in the market
P/E
Price per share divided by earnings per share
ROE
Net income divided by shareholder equity
ROCE
Earnings before interest and tax divided by capital employed
Debt/Eq
Total debt divided by total equity
Profit 5Y
Average annual profit growth over 5 years
Sales 5Y
Average annual sales growth over 5 years
Dividend
Annual dividend per share divided by price per share
39.5/100
17
₹27.46
8.0
Average
10.61%
Average
13.62%
Average
0.1
Excellent
35.10%
Excellent
6.96%
Good
1.93%
55.6/100
1702
₹17395.50
53.2
Average
11.15%
Average
14.04%
Average
0.1
Excellent
19.35%
Excellent
19.02%
Excellent
0.20%
21.9/100
39
₹2522.43
81.3
Average
8.59%
Poor
11.43%
Average
0.3
Excellent
0.01%
17.1/100
315
₹1588.16
105.5
Average
2.38%
Poor
4.56%
Poor
0.6
Good
-26.20%
Poor
13.04%
Good
0.00%
69.6/100
213
₹1227.22
36.7
Average
14.80%
Average
14.86%
Average
0.1
Excellent
103.10%
Excellent
24.69%
Excellent
0.00%
67.9/100
413
₹782.87
26.8
Average
19.56%
Good
24.40%
Excellent
0.5
Excellent
84.72%
Excellent
38.54%
Excellent
0.00%
64.4/100
376
₹547.99
30.1
Average
18.19%
Good
19.64%
Good
0.4
Excellent
68.05%
Excellent
31.02%
Excellent
0.00%
61.5/100
402
₹465.72
21.7
Average
18.51%
Good
24.67%
Excellent
0.0
Excellent
24.33%
Excellent
20.33%
Excellent
0.26%
38.2/100
147
₹285.51
56.6
Average
7.54%
Poor
12.64%
Average
0.1
Excellent
42.43%
Excellent
16.12%
Excellent
0.00%
Nureca Ltd...
NURECA543264
16.5/100
344
₹260.07
123.8
Average
1.12%
Poor
3.30%
Poor
0.0
Excellent
-46.15%
Poor
-7.19%
Poor
0.00%
20.7/100
111
₹216.85
21.4
Average
10.45%
Average
13.18%
Average
0.7
Good
0.45%

Galaxy Medicare Quarterly Performance

Latest quarterly metrics for GML — revenue growth and profit growth vs same quarter last year

Revenue Growth (YoY)

-3.14%

Latest quarter vs same quarter previous year

Net Profit Growth (YoY)

-15.66%

Latest quarter net profit vs same quarter previous year

5-Year Revenue CAGR

6.96%

Compounded annual revenue growth over 5 years

5-Year Profit CAGR

35.10%

Compounded annual net profit growth over 5 years

Galaxy Medicare Technical Indicators

SMA 50, SMA 200, RSI and volume signals for GML — calculated from daily price history

26RSI 14
Oversold — RSI 26

Selling pressure is heavy — potential reversal zone.

SMA 50
19
▼ Price below SMA 50 — Short-term bearish
30-Day Avg Volume
10K shares/day
Average daily traded volume over last 30 trading sessions

Technical indicators are for educational purposes only. Not investment advice.

Galaxy Medicare Financial Statements

Annual income statement, balance sheet and cash flow for Galaxy Medicare (GML) — sourced from NSE/BSE filings.

Loading Financial Statements...

Fetching financial data for Galaxy Medicare

About GML (Galaxy Medicare)

Galaxy Medicare (GML) is listed on the National Stock Exchange (NSE) and Bombay Stock Exchange (BSE) of India. The company operates in the Medical Equipment & Supplies sector with ...a current market capitalisation of ₹27.46 (Cr). Galaxy Medicare has delivered a Return on Equity (ROE) of 10.61% and a ROCE of 13.62%. The debt-to-equity ratio stands at 0.10, reflecting the company's capital structure. Investors tracking GML share price can monitor key metrics including P/E ratio, promoter holding of 72.98%, and quarterly earnings growth.

Company Details

Symbol:GML
Industry:Medical Equipment & Supplies
Sector:Medical Equipment & Supplies
Website:N/A

GML Share Price: Frequently Asked Questions

What is the current share price of Galaxy Medicare?

Galaxy Medicare (GML) trades at ₹16.70 on NSE. Market cap ₹27.46 (Cr). Educational data only.

What is the P/E ratio of Galaxy Medicare?

Galaxy Medicare has a P/E of 8.03x vs industry average 36.70x.

What is the Bull Run score for Galaxy Medicare?

Galaxy Medicare has a Bull Run score of 39.5/100 based on 25+ financial parameters.

Does Galaxy Medicare pay dividends?

Galaxy Medicare has a dividend yield of 1.93%. Past dividends don't guarantee future payments.

What is the ROE of Galaxy Medicare?

Galaxy Medicare has ROE of 10.61%. Higher ROE indicates better use of shareholder equity.

What is the debt-to-equity ratio of Galaxy Medicare?

Galaxy Medicare has debt-to-equity of 0.10.

Is Galaxy Medicare a good investment?

Bull Run gives Galaxy Medicare a score of 39.5/100. This is not investment advice — consult a SEBI-registered advisor.